Introduction：Basic information about CAS 14116-68-8|Lacto-N-tetraose, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lacto-N-tetraose |
|---|
| CAS Number | 14116-68-8 | Molecular Weight | 707.63000 |
|---|
| Density | 1.76g/cm3 | Boiling Point | 1116.1ºC at 760 mmHg |
|---|
| Molecular Formula | C26H45NO21 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 628.8ºC |
|---|
Names
| Name | lacto-n-tetraose |
|---|
| Synonym | More Synonyms |
|---|
Lacto-N-tetraose BiologicalActivity
| Description | Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula[1]. |
|---|
| Related Catalog | Research Areas >>InfectionResearch Areas >>Inflammation/ImmunologySignaling Pathways >>Anti-infection >>Bacterial |
|---|
| In Vitro | HMOs exhibits antimicrobial and antibiofilm activity against Streptococcus agalactiae, antibiofilm activity against Methicillin-resistant Staphylococcus aureus (MRSA), and antimicrobial activity against both Acinetobacter baumannii and Clostridium difficile[2]. Lacto-N-tetraose (500-2000 μg/mL) does not cause clastogenic or aneugenic signs in human peripheral blood lymphocytes, nor increase the percentage of micronucleated cells[3]. |
|---|
| In Vivo | Lacto-N-tetraose (1000-4000 mg/kg; p.o.; daily for 90 days) does not show toxicity in neonatal SD rats[3]. Animal Model: Female neonatal SD rats (housed together with dam until weaning after 21 days)[3] Dosage: 1000, 25000 and 4000 mg/kg Administration: p.o.; daily for 90 days Result: Did not show toxicity on clinical observations, body weight, food consumption, development and maturation, clinical pathology, organ weights or histopathology. |
|---|
| References | [1]. Zhu Y, et al. Physiological effects, biosynthesis, and derivatization of key human milk tetrasaccharides, lacto-N-tetraose, and lacto-N-neotetraose. Crit Rev Biotechnol. 2022 Jun;42(4):578-596. [2]. Craft KM, Thomas HC, Townsend SD. Sialylated variants of lacto-N-tetraose exhibit antimicrobial activity against Group B Streptococcus. Org Biomol Chem. 2019 Feb 13;17(7):1893-1900. [3]. Phipps KR, et al. Preclinical safety evaluation of the human-identical milk oligosaccharide lacto-N-tetraose. Regul Toxicol Pharmacol. 2018 Nov;99:260-273. |
|---|
Chemical & Physical Properties
| Density | 1.76g/cm3 |
|---|
| Boiling Point | 1116.1ºC at 760 mmHg |
|---|
| Molecular Formula | C26H45NO21 |
|---|
| Molecular Weight | 707.63000 |
|---|
| Flash Point | 628.8ºC |
|---|
| Exact Mass | 707.24800 |
|---|
| PSA | 356.70000 |
|---|
| Vapour Pressure | 0mmHg at 25°C |
|---|
| Index of Refraction | 1.668 |
|---|
| InChIKey | AXQLFFDZXPOFPO-OYNOJIEESA-N |
|---|
| SMILES | CC(=O)NC1C(OC2C(O)C(CO)OC(OC3C(CO)OC(O)C(O)C3O)C2O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O |
|---|
Safety Information
Synonyms
| fromhumanmilk |
| GAL-BETA1,3GLCNAC-BETA1,3GAL-BETA1,4GLC |
| LNT-GEL |
| LNT |
| LACTO-N-TETRAOSE FROM HUMAN MILK |
| LCOSE4 |
| LNT-KLH |
